Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

Cited by (123)

Items 101–123 of 123

1. Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance
   Julia S. Schneider, Najib Ben Khaled, Liangtao Ye, Ralf Wimmer, Linda Hammann, Alexander Weich, Christoph Suppan, Ujjwal Mukund Mahajan, Andreas Jung, Jörg Kumbrink et al. · 2025 · Cellular Oncology
2. Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract
   FUCHUN ZENG, Yubin Zhou, THEERAWAT KHOWTANAPANICH, Charupong Saengboonmee · 2022 · In Vivo
3. Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities
   Wei Yen Chan, Ines Pires da Silva, Georgina Venetia Long, Helen Rizos · 2026 · The Lancet
4. Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer
   Priya Jayachandran, Andrew Elliott, Shivani Soni, Francesca Battaglin, Pooja Mittal, Sandra Algaze, Jae Ho Lo, Yan Yang, Karam Ashouri, Evanthia T. Roussos Torres et al. · 2025 · Oncogene
5. Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells
   Maj-Britt Paulsohn, Klara Henrike Frahnert, Denise Schlösser, Joana Oschwald, Waltraut Kopp, Xin Fang, Carolin Schneider, Constanza Tapia Contreras, Adi Danieli‐Mackay, Fabian Ludewig et al. · 2025 · Cell Death and Disease
6. Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS -mutated colorectal cancer
   Susmita Ghosh, Fan Fan, Reid Trenton Powell, Yong Sung Park, CLIFFORD C. STEPHAN, Scott Kopetz, Lee M. Ellis, Rajat Bhattacharya · 2024 · Therapeutic Advances in Medical Oncology
7. Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma
   Rayan Kabirian, Thomas Gaillard, Diana Bello-Roufai, Caroline Malhaire, Virginie Huchet, Céline Callens, Benjamine Pham, Enrica Bentivegna, Bruno Borghese, Enora Laas et al. · 2025 · Bulletin du Cancer
8. Prognostic Significance of Cyclin D1 Expression in Small Intestinal Adenocarcinoma
   Sun‐Young Jun, Seung‐Mo Hong, Kee‐Taek Jang · 2023 · Cancers
9. Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models
   Yusuke Tomita, Gabrielle Link, Yi Ge, Emma R.H. Gold, Herminio Joey Cardona, Megan M. Romero, Samantha Gadd, Jun Watanabe, Eita Uchida, Rintaro Hashizume et al. · 2025 · PLoS ONE
10. An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development
    Shadi Chamseddine, Asfar Sohail Azmi, M. W. Saif · 2025 · Expert Opinion on Investigational Drugs
11. Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial
    Britta Julia Vormoor, Joshua Savage, Caroline Kristunas, Sarah Z. Johnson, Mauricio Nicolás Ferrao Blanco, Geoff Shenton, Donna Lancaster, Anna Z. Castleton, Adele Kay Fielding, Anne‐Louise Latif et al. · 2026 · EJC Paediatric Oncology
12. Cell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis
    Yuanjie Fu, Ying Wang, Shunjing Wu, Yi Ying, J N Li, Yanghuan Ou, Yinying Wang, Li Li, Yueying Wu, Jinyuan Yan et al. · 2026 · Frontiers in Immunology
13. Network Entropy Reveals that Cancer Resistance to MEK Inhibitors Is Driven by the Resilience of Proliferative Signaling
    Joel D. Maust, Judith Leopold, Andrej E. Bugrim · 2019 · Studies in computational intelligence
14. Anaphase-Promoting Complex Adaptor FZR1/CDH1 Blocks BRAF Signaling Both by Targeting BRAF for Proteolytic Degradation and by Disrupting BRAF Dimerization
    Chao Zhang, Gideon E. Bollag · 2017 · Cancer Discovery
15. Research Progress of CDK4/6 Inhibitors in Digestive Tract Tumors
    ·斯提瓦尔地 伊丽达娜 · 2023 · Advances in Clinical Medicine
16. Dual Inhibitors of CDK4 /6 for Treating Cancer
    Peter L. Toogood · 2024 · Wiley eBooks
17. The Inhibition of CDK4/6 regulates the activity of multidrug resistance pumps in glioblastoma
    Yusuf Yilmaz, Hacer Ağar, Kaan Furkan Hamarat, Gamze Tanrιöver, Gamze Güney Eskiler · 2025 · Cytotechnology
18. Intratumoral plasma cells mediate CD8+ T cell infiltration and successful immune checkpoint blockade therapy in de novo MPNSTs
    Joshua J. Lingo, Ryan J. Reis, Chantal Allamargot, Juan A. Raygoza Garay, Courtney A. Kaemmer, Elizabeth C. Elias, Ellen M. Voigt, Ali Jabbari, Connor R. Wilhelm, Alexander W. Boyden et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
19. From undruggable to actionable: advances in KRAS targeting in colorectal cancer
    Mei Chan, Meghna Shelke, Amanda Rose Townsend, Amitesh Chandra Roy, Vy Tuong Broadbridge, Christos Stelios Karapetis, T. J. Price · 2026 · Academia oncology.
20. Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma
    Lisa Mayr, Leah Mager, Lisa Gabler, Dominik Kirchhofer, Julia Freund, Kallen Schwark, Benison C. Lau, Sarah Machreich, Daniel Senfter, Mia Neumüller et al. · 2026 · Journal of Experimental & Clinical Cancer Research
21. CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions
    Mengying Guan, Hua Hao · 2026 · Cancers
22. Intratumoural plasma cells mediate a pro-inflammatory response to kinase inhibition and successful immune checkpoint blockade therapy in malignant peripheral nerve sheath tumours
    Joshua J. Lingo, Ryan Reis, Altay Koyaş, Ellen M. Voigt, Zeb Ralph Zacharias, Chantal Allamargot, Emma E. Hornick, Juan A. Raygoza Garay, Courtney A. Kaemmer, Elizabeth C. Elias et al. · 2026 · EBioMedicine
23. Ligand-based pharmacophore modeling and molecular dynamics driven discovery of novel MEK1 inhibitors targeting KRAS signalling pathway
    Krishna Kalaskar, Rajasekhar Reddy Alavala · 2026 · Journal of Molecular Graphics and Modelling